Table 1.
Association of the presence of depressive symptoms at baseline with time until start of dialysis, all-cause mortality and a combined adverse event, after imputation of MHI-5 score and baseline confounders
| Entire cohort | Males | Females | ||||
|---|---|---|---|---|---|---|
| Outcome | Crude HR (95% CI) | Adjusted HRa (95% CI) | Crude HR (95% CI) | Adjusted HRa (95% CI) | Crude HR (95% CI) | Adjusted HRa (95% CI) |
| N = 1708 | N = 1708 | N = 1114 | N = 1114 | N = 594 | N = 594 | |
| Start of dialysis | 1.02 (0.83–1.24) | 1.01 (0.79–1.28) | 1.10 (0.87–1.40) | 1.01 (0.77–1.33) | 1.09 (0.73–1.62) | 1.19 (0.78–1.82) |
| All-cause mortality | 1.31 (1.03–1.66)* | 1.20 (0.93–1.55) | 1.48 (1.10–1.99)** | 1.22 (0.92–1.60) | 1.15 (0.78–1.69) | 1.06 (0.71–1.56) |
| Combined adverse outcomeb | 1.14 (0.97–1.33) | 1.10 (0.91–1.32) | 1.25 (1.04–1.50)* | 1.13 (0.92–1.39) | 1.12 (0.84–1.49) | 1.11 (0.81–1.51) |
The hazard ratio (95% confidence interval) indicates the increased rate of an event (start of dialysis, all-cause mortality and combined adverse outcome) for the presence of depressive symptoms at baseline (i.e. a score ≤70 on the MHI-5).
aAdjusted for: age, gender, ethnicity, level of education, primary kidney disease (PKD), Charlson Comorbidity Index (CCI), body mass index (BMI), smoking status, subjective global assessment (SGA), estimated glomerular filtration rate (eGFR) at baseline, and plasma albumin and urea levels.
bCombined adverse outcome: either start of dialysis or all-cause mortality.
*P < 0.05, **P < 0.01.